OncoBayes2: OncoBayes2

In OncoBayes2: Bayesian Logistic Regression for Oncology Dose-Escalation Trials

OncoBayes2

Description

Bayesian logistic regression model with optional EXchangeability-NonEXchangeability parameter modelling for flexible borrowing from historical or concurrent data-sources. The safety model can guide dose-escalation decisions for adaptive Oncology phase I dose-escalation trials which involve an arbitrary number of drugs.

Global Options

Option	Default	Description
OncoBayes2.MC.warmup	1000	MCMC warmup iterations
OncoBayes2.MC.iter	2000	total MCMC iterations
OncoBayes2.MC.save_warmup	TRUE	save warmup samples
OncoBayes2.MC.chains	4	MCMC chains
OncoBayes2.MC.thin	1	MCMC thinning
OncoBayes2.MC.control	list(adapt_delta=0.99,	sets control argument for Stan call
	stepsize=0.1)
OncoBayes2.MC.backend	rstan	Backend used to run Stan (rstan or cmdstanr)
OncoBayes2.abbreviate.min	0	Minimal length of variable names
		when abbreviating variable names.
		The default 0 disables abbreviation.

References

Neuenschwander, B., Roychoudhury, S., & Schmidli, H. (2016). On the use of co-data in clinical trials. Statistics in Biopharmaceutical Research, 8(3), 345-354.

Neuenschwander, B., Wandel, S., Roychoudhury, S., & Bailey, S. (2016). Robust exchangeability designs for early phase clinical trials with multiple strata. Pharmaceutical statistics, 15(2), 123-134.

Neuenschwander, B., Branson, M., & Gsponer, T. (2008). Critical aspects of the Bayesian approach to phase I cancer trials. Statistics in medicine, 27(13), 2420-2439.

Neuenschwander, B., Matano, A., Tang, Z., Roychoudhury, S., Wandel, S. Bailey, Stuart. (2014). A Bayesian Industry Approach to Phase I Combination Trials in Oncology. In Statistical methods in drug combination studies (Vol. 69). CRC Press.

Stan Development Team (2019). RStan: the R interface to Stan. R package version 2.19.2. https://mc-stan.org

OncoBayes2 documentation built on July 26, 2023, 5:30 p.m.